HIGHLIGHTS
- who: Luke Milross and colleagues from the Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne , RU, UK have published the research work: Ex Vivo Lung Perfusion: A Platform for Donor Lung Assessment, Treatment and Recovery, in the Journal: Transplantology 2021, 2, 387-395. of /2021/
- what: This trial had a lung utilisation rate of 87%, far surpassing the utilisation rate found in current clinical practice.
- future: The Future Potential for EVLP EVLP offers logistical advantages through the extension of preservation time without extending cold ischaemic time meaning operations might be performed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.